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Abstract
Objective: Periodontal disease is accompanied by inflammation of the gingiva and destruction of periodontal
tissues, leading to alveolar bone loss in severe clinical cases. Interleukin (IL)-6, IL-8, and the chemical mediator
prostaglandin E2 (PGE2) are known to play important roles in inflammatory responses and tissue degradation.
Recently, we reported that the protein kinase A (PKA) inhibitor H-89 suppresses lipopolysaccharide (LPS)-induced
IL-8 production by human gingival fibroblasts (HGFs). In the present study, the relevance of the PKA activity and
two PKA-activating drugs, aminophylline and adrenaline, to LPS-induced inflammatory cytokines (IL-6 and IL-8) and
PGE2 by HGFs were examined.
Methods: HGFs were treated with LPS from Porphyromonas gingivalis and H-89, the cAMP analog dibutyryl cyclic
AMP (dbcAMP), aminophylline, or adrenaline. After 24 h, IL-6, IL-8, and PGE2 levels were evaluated by ELISA.
Results: H-89 did not affect LPS-induced IL-6 production, but suppressed IL-8 and PGE2 production. In contrast,
dbcAMP significantly increased LPS-induced IL-6, IL-8, and PGE2 production. Up to 10 μg/ml of aminophylline did
not affect LPS-induced IL-6, IL-8, or PGE2 production, but they were significantly increased at 100 μg/ml. Similarly,
0.01 μg/ml of adrenaline did not affect LPS-induced IL-6, IL-8, or PGE2 production, but they were significantly
increased at concentrations of 0.1 and 1 μg/ml. In the absence of LPS, H-89, dbcAMP, aminophylline, and
adrenaline had no relevance to IL-6, IL-8, or PGE2 production.
Conclusion: These results suggest that the PKA pathway, and also PKA-activating drugs, enhance LPS-induced IL-6,
IL-8, and PGE2 production by HGFs. However, aminophylline may not have an effect on the production of these
molecules at concentrations used in clinical settings (8 to 20 μg/ml in serum). These results suggest that
aminophylline does not affect inflammatory responses in periodontal disease.
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Background
Periodontal disease is accompanied by inflammation of
the gingiva and destruction of periodontal tissues, lead-
ing to alveolar bone loss in severe clinical cases. Inter-
leukin (IL)-6, IL-8, and prostaglandin E2 (PGE2) are
known to play important roles in inflammatory
responses and tissue degradation. IL-6 has the ability to
induce osteoclastogenesis [1,2]. IL-8 acts as a chemoat-
tractant for neutrophils [3] that produce proteases such
as cathepsin, elastase, or matrix metalloproteinase
(MMP)-8, leading to tissue degradation. PGE2 has sev-
eral functions in vasodilation, the enhancement of vas-
cular permeability and pain, and the induction of
osteoclastogenesis, and is believed to play important
roles in inflammatory responses and alveolar bone
resorption in periodontal disease [4].
Recently, we reported that the protein kinase A (PKA)
inhibitor H-89 suppresses LPS-induced IL-8 production
by human gingival fibroblasts (HGFs) [5]. This finding
suggests that the PKA pathway enhances LPS-induced
IL-8 production, and that taking PKA-activating drugs
results in an increase of inflammatory cytokines
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production, and further, the exacerbation of periodontal
disease. PKA-activating drugs are xanthine derivatives
and b-adrenergic agonists. Xanthine derivatives such as
theophylline and aminophylline inhibit the cAMP-
degrading enzyme phosphodiesterase (PDE), increase
intracellular cAMP, and then activate the PKA pathway
[6]. These drugs are clinically used as cardiotonic agents
for cardiac failure or as bronchodilator agents for chronic
obstructive pulmonary disease. In contrast, b-adrenergic
agonists activate adenylate cyclase, increase intracellular
cAMP, and then activate the PKA pathway. Because
withdrawal of these drugs, in particular xanthine deriva-
tives, leads to exacerbation of cardiac failure and chronic
obstructive pulmonary disease, withdrawal is difficult in
patients having these diseases. For these reasons, there is
a need to examine whether these drugs affect the inflam-
matory responses in periodontal disease.
HGFs are the most prominent cells in periodontal tis-
sue. And LPS-treated HGFs produce inflammatory cyto-
kines such as IL-6 and IL-8, and inflammatory chemical
mediators such as PGE2 [1,7,8].
Moreover, because HGFs have sustained production of
IL-6 and IL-8 [9] and PGE2 [10] in the presence of LPS,
these mediators and cytokines in periodontal tissues are
thought to be derived from HGFs.
Therefore, we believe that examining the effects of
these drugs on HGFs, as well as on monocytes and
macrophages, is important in the study of periodontal
disease. In the present study, we examined the relevance
of the PKA activity, and of drugs activating the PKA
pathway (aminophylline and adrenaline), to LPS-induced
IL-6, IL-8, and PGE2 production by HGFs.
Results
Relevance of the PKA activity to LPS-induced IL-6, IL-8,
and PGE2 production
First, we examined whether the PKA inhibitor H-89
affects the production of inflammatory cytokines (IL-6
and IL-8) and PGE2 by HGFs. Because our previous
report has shown that H-89 suppresses LPS-induced IL-
8 production [5], we used this result as control in this
study. H-89 showed little or no effect on cell viability in
the absence or presence of LPS at 24 h after stimulation
(Figure 1A). In the absence of LPS, H-89 did not affect
IL-6, IL-8, or PGE2 production (Figure 1B-D). When
HGFs were treated with 10 ng/ml of LPS, HGFs pro-
duced large amounts of IL-6, IL-8, and PGE2. Up to 10
μM of H-89 did not affect LPS-induced IL-6 production,
but decreased IL-8 and PGE2 production (Figure 1B-D).
Next, we examined whether the cAMP analog
dbcAMP affects the production of IL-6, IL-8, and PGE2
by HGFs. dbcAMP also showed little or no effect on
cell viability in the absence or presence of LPS at 24 h
after stimulation (Figure 2A). In the absence of LPS,
Figure 1 Relevance of PKA inhibition to HGFs viability and the
production of IL-6, IL-8, and PGE2. HGFs were treated with
combinations of LPS (0 and 10 ng/ml) and H-89 (0, 0.1, 1, and 10
μM) for 24 h. (A) Viable cell numbers were measured using WST-8
and are expressed as OD-blank (mean ± S.D., n = 3). (B-D) The
concentrations of IL-6, IL-8, and PGE2 were measured by ELISA. The
concentrations were adjusted by the viable cell numbers (A) and
are expressed as ng or pg per 10,000 cells (mean ± S.D., n = 3). (B)
IL-6, (C) IL-8, and (D) PGE2. Open bars, treatment without LPS;
closed bars, treatment with 10 ng/ml of LPS. P values were
calculated by the pairwise comparison test corrected with the Holm
method (6 null hypotheses).
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dbcAMP did not affect IL-6, IL-8, or PGE2 production
(Figure 2B-D). In contrast, dbcAMP significantly
increased LPS-induced IL-6, IL-8, and PGE2 production
in a dose-dependent-manner (Figure 2B-D).
Relevance of drugs that activate the PKA pathway to LPS-
induced IL-6, IL-8, and PGE2 production
Because dbcAMP enhanced LPS-induced IL-6, IL-8, and
PGE2 production, we examined the effects of amino-
phylline and adrenaline, which both increase intracellu-
lar cAMP concentrations and activate the PKA pathway,
on IL-6, IL-8, and PGE2 production. Both aminophylline
and adrenaline showed little or no effect on cell viability
in the absence or presence of LPS (Figure 3A and 4A).
In the absence of LPS, aminophylline and adrenaline did
not affect IL-6, IL-8, or PGE2 production (Figure 3B-D
and 4B-D). Up to 10 μg/ml of aminophylline did not
affect LPS-induced IL-6, IL-8, or PGE2 production, but
they were significantly increased at 100 μg/ml (Figure
3B-D). Similarly, 0.01 μg/ml of adrenaline did not affect
LPS-induced IL-6, IL-8, or PGE2 production, but they
were significantly increased at concentrations of 0.1 and
1 μg/ml (Figure 4B-D).
Discussion
In the present study, we examined the relevance of the
PKA activity to LPS-induced IL-6, IL-8, and PGE2 pro-
duction. We showed that the PKA inhibitor H-89 sup-
pressed LPS-induced IL-8 and PGE2 production, and
that the PKA activator dbcAMP enhanced LPS-induced
IL-6, IL-8, and PGE2 production. Moreover, we showed
that aminophylline and adrenaline enhanced this pro-
duction. However, H-89, dbcAMP, aminophylline, and
adrenaline had no relevance to the production of these
molecules in the absence of LPS. These results suggest
that the PKA pathway enhances the LPS signaling path-
way in HGFs, but that the PKA pathway alone does not
enhance LPS-induced IL-6, IL-8, and PGE2 production.
Several reports have demonstrated the relevance of
LPS to the PKA activity. LPS enhances cAMP accumula-
tion in a mouse pituitary cell line [11] and in human
bladder epithelial cells [12]. Moreover, LPS enhances
cAMP response element binding protein (CREB) phos-
phorylation and its DNA-binding ability, and these
activities are inhibited by H-89 [13]. Although there is
no comparable report for HGFs, a similar mechanism
may be present.
Additionally, various reports have shown the relevance
of the PKA activity to IL-6, IL-8, and PGE2 production.
However, whether the PKA pathway enhances or sup-
presses their production is different in depending on the
cell type and genes in question. (1) The PKA pathway
enhances LPS-induced IL-6 production. For instance,
calcitonin gene-related peptide, which increases cAMP
Figure 2 Relevance of PKA activation to HGFs viability and the
production of IL-6, IL-8, and PGE2. HGFs were treated with
combinations of LPS (0 and 10 ng/ml) and dbcAMP (0, 1, 10, and
100 μM) for 24 h. (A) Viable cell numbers were measured using
WST-8 and are expressed as OD-blank (mean ± S.D., n = 3). (B-D)
The concentrations of IL-6, IL-8, and PGE2 were measured by ELISA.
The concentrations were adjusted by the viable cell numbers (A)
and are expressed as ng or pg per 10,000 cells (mean ± S.D., n = 3).
(B) IL-6, (C) IL-8, and (D) PGE2. Open bars, treatment without LPS;
closed bars, treatment with 10 ng/ml of LPS. P values were
calculated by the pairwise comparison test corrected with the Holm
method (6 null hypotheses).
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Figure 3 Relevance of aminophylline to HGFs viability and the
production of IL-6, IL-8, and PGE2. HGFs were treated with
combinations of LPS (0 and 10 ng/ml) and aminophylline (0, 1, 10,
and 100 μg/ml) for 24 h. (A) Viable cell numbers were measured
using WST-8 and are expressed as OD-blank (mean ± S.D., n = 3).
(B-D) The concentrations of IL-6, IL-8, and PGE2 were measured by
ELISA. The concentrations were adjusted by the viable cell numbers
(A) and are expressed as ng or per 10,000 cells (mean ± S.D., n = 3).
(B) IL-6, (C) IL-8, and (D) PGE2. Open bars, treatment without LPS;
closed bars, treatment with 10 ng/ml of LPS. P values were
calculated by the pairwise comparison test corrected with the Holm
method (6 null hypotheses).
Figure 4 Relevance of adrenaline to HGFs viability and the
production of IL-6, IL-8, and PGE2. HGFs were treated with
combinations of LPS (0 and 10 ng/ml) and adrenaline (0, 0.01, 0.1,
and 1 μg/ml) for 24 h. (A) Viable cell numbers were measured using
WST-8 and are expressed as OD-blank (mean ± S.D., n = 3). (B-D)
The concentrations of IL-6, IL-8, and PGE2 were measured by ELISA.
The concentrations were adjusted by the viable cell numbers (A)
and are expressed as ng or pg per 10,000 cells (mean ± S.D., n = 3).
(B) IL-6, (C) IL-8, and (D) PGE2. Open bars, treatment without LPS;
closed bars, treatment with 10 ng/ml of LPS. P values were
calculated by the pairwise comparison test corrected with the Holm
method (6 null hypotheses).
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accumulation, enhances LPS-induced IL-6 production in
mouse peritoneal macrophages [14], and H-89 sup-
presses IL-6 expression in human blood monocytes [15].
In the present study, dbcAMP, aminophylline, and adre-
naline enhanced LPS-induced IL-6 production by HGFs
to the same extent as by monocytes and macrophages in
previous reports [14,15]. In contrast, H-89 had no rele-
vance to LPS-induced IL-6 production. The reasons for
this discrepancy remain to be elucidated. However, we
assume that the enhancement of PKA activity by LPS
treatment is weak in HGFs. (2) The relevance of the
PKA activity to IL-8 production are different among
several previous reports. The PKA pathway suppresses
LPS-induced IL-8 production, i.e. b-adrenergic agonists
and dbcAMP suppress and H-89 enhances LPS-induced
IL-8 production by human monocytic THP-1 cells [16].
In contrast, cAMP analogs have been shown to have no
relevance to LPS-induced IL-8 production by human
macrophages [17] and by human peripheral blood
mononuclear cells [18]. Our results showing that the
PKA pathway enhanced LPS-induced IL-8 production
by HGFs is different from these previous reports, and
therefore may be an important characteristic of HGFs.
(3) The PKA pathway enhances LPS-induced PGE2 pro-
duction. dbcAMP enhanced LPS-induced cyclooxygen-
ase-2 (COX-2) expression and PGE2 production by
human blood moncytes [19] and mouse RAW264.7
macrophage cell line [20]. In contrast, H-89 suppresses
LPS-induced COX-2 expression in RAW264.7 cells [21],
These results are consistent to our results with HGFs.
Next, we discuss whether aminophylline at a concen-
tration used in clinic enhances the inflammatory
response in periodontal disease. The serum concentra-
tions of theophylline in the therapeutic range are 8 to
20 μg/ml [6,22,23]. Concentrations of theophylline
above 20 μg/ml lead to adverse effects such as arrhyth-
mia, convulsion, and central nervous symptoms, and
concentrations above 60 μg/ml lead to death [6]. The
therapeutic range of aminophylline is considered to be
similar to that of theophylline, because aminophylline is
a dimer of theophylline. In the present study, up to 10
μg/ml of aminophylline did not affect LPS-induced IL-6,
IL-8, or PGE2 production. Moreover, although 100 μg/
ml of aminophylline enhanced LPS-induced production
of these molecules, this concentration of aminophylline
is fatal. Therefore, it is unlikely that aminophylline
enhances the inflammatory response and exacerbates
periodontal disease. Moreover, we conclude that only
aminophylline among the drugs we tested does not
induce inflammatory responses.
Conclusion
We demonstrated that the PKA pathway, and also the
PKA-activating drugs aminophylline and adrenaline,
enhance LPS-induced IL-6, IL-8, and PGE2 production
by HGFs. However, aminophylline had no relevance to
the production of these molecules at a concentration
used in clinic (or the therapeutic range). These results
suggest that aminophylline does not affect inflammatory
responses in periodontal disease.
Materials and methods
Reagents
PKA inhibitor H-89 (Sigma, St. Louis, MO) was dis-
solved in dimethyl sulfoxide (DMSO, Nacalai Tesque,
Kyoto, Japan). The cAMP analog dibutyryl cyclic AMP
(dbcAMP) and adrenaline [(±)-epinephrine] were pur-
chased from Wako (Osaka, Japan), and aminophylline
dihydrate from MP Biomedicals (Illkirch, France). LPS
from Porphyromonas gingivalis 381 was provided by
Drs. Tatsuji Nishihara and Nobuhiro Hanada (National
Institutes of Public Health, Wako, Japan).
Cells
HGFs were prepared as described previously [24]. In
brief, HGFs were prepared from free gingiva during the
extraction of an impacted tooth with the informed con-
sent of the subjects who consulted Matsumoto Dental
University Hospital. The free gingival tissues were cut
into pieces and seeded onto 24-well plates (AGC
Techno Glass Co., Chiba, Japan). HGFs were maintained
in Dulbecco’s modified Eagle’s medium (D-MEM;
Sigma) containing 10% heat-inactivated fetal calf serum
(FCS), 100 units/ml penicillin, and 100 μg/ml strepto-
mycin, at 37°C in a humidified atmosphere of 5% CO2.
For passage, HGFs were trypsinazed, suspended, and
plated onto new cultures in a 1:3 dilution ratio. HGFs
were used between 15th to 20th passages in the assays.
Although the proliferation rate was slightly slowed at
later passages, the apparent morphological changes were
not observed. This study was approved by the Ethical
Committee of Matsumoto Dental University (No. 0063).
Cytokine measurement by enzyme-linked immunosorbent
assay (ELISA)
HGFs (10,000 cells/well) were seeded in 96-well plates
(AGC Techno Glass Co., Chiba, Japan) and incubated in
serum-containing medium at 37°C overnight. Then, the
cells were treated with various concentrations of drugs
in the absence or presence of LPS (10 ng/ml) for 24 h
(200 μl each well). In the experiments using H-89, the
cells were pretreated with H-89 (0.1, 1, and 10 μM) or
an equal volume of DMSO for 60 min, followed by
treatment with a combination of LPS (0 or 10 ng/ml)
and H-89 (the same concentration as pretreatment) for
24 h. The concentration of each reagent was determined
as the high-frequency concentration according to several
previous reports. After the culture supernatants were
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collected, viable cell numbers were measured using
WST-8 (Cell Counting Kit-8; Dojindo, Kumamoto,
Japan) according to the manufacturer’s instructions. The
concentrations of IL-6, IL-8, and PGE2 in the culture
supernatants were measured by ELISA according to the
manufacturers’ instructions (IL-6 and IL-8, Biosource
International Inc., Camarillo, CA; PGE2, Cayman Che-
mical, Ann Arbor, MI), and were adjusted by the num-
ber of remaining cells. Data are represented as ng or pg
per 10,000 cells (mean ± S.D., n = 3).
Statistical analysis
Differences between groups were evaluated by the pair-
wise comparison test corrected with the Holm method
(3 + 3 null hypotheses without drug vs. with drugs in
the absence or presence of LPS; total 6 null hypotheses).
All computations were performed with the statistical
program R [25]. Values with P < 0.05 were considered
as significantly different.
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